The Great 2023 Humira Biosimilars Watch Is On – Here’s Where to Focus
Up to 10 competing products for Humira are on the way in 2023. What should health plans and plan sponsors be following as the biosimilars landscape takes shape?
Menu
Uncategorized
Humira and the Looming Biosimilar Boom
A wave of FDA-approved biosimilars for Humira and other costly biologics will enter the U.S. market in 2023. What does it mean for patients, payers and plan designs?
A Glimpse of the Holy Grail for Healthcare Cost Transparency
Seemingly since the beginning of time, consumers have rarely known what a doctor visit, medical procedure or medication will cost until it’s time to pay. Fortunately, things are starting to change.
Why Are the Most Important Rx Decision-makers Still in the Dark?
The only people who can write prescriptions typically have no idea what patients will pay at the pharmacy. It’s time to solve this problem.
Generic Dexilant® Joins the PPI Party, But Plenty of Alternatives Already Have
A widely prescribed acid reflux medication now has an authorized generic available. Good news, but five low-cost proton-pump inhibitor (PPIs) generics often work just as well.
Whatever the Numbers Say, Guess Who Keeps Paying More for Rx?
January produced another price hike party from drug makers. But some data indicate prescription prices are actually falling. For consumers? Same as it ever was, or worse.
A Little Joy Goes a Long Way
A $100 gift may not go as far as it once did, but the only inflation this holiday season was in the hearts of hundreds of RxSS employees and clients who gave their gifts to others.
